Elevance Health stock edges higher as full-year 2026 EPS guidance is reaffirmed
Published on 09/15/2026 at 17:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health Inc. stock (ISIN US2855211023) traded at about USD 423.00 on the New York Stock Exchange on September 15, 2026, modestly higher within the day’s range after the company reaffirmed its full-year 2026 earnings guidance, a signal closely watched by investors ahead of upcoming investor meetings, according to Robinhood.
Guidance reaffirmation supports 2026 earnings visibility
As Robinhood reports, Elevance Health shares were described as moving higher after management reaffirmed its full-year 2026 earnings per share guidance ahead of a series of investor meetings, underscoring confidence in the company’s ability to deliver on its profit targets for the current year.
In parallel with the EPS guidance, Elevance’s leadership has been sharpening its focus on profitability in key segments. According to Becker's Hospital Review on September 15, 2026, CEO Gail Boudreaux stated that the company is aiming for at least a 2 percent operating margin in its Medicare Advantage business in 2026, highlighting disciplined plan design and care management programs as drivers for that target.
Segment margins and Medicaid remain key risk factors
The focus on segment profitability comes alongside challenges in other lines of business. As Becker's Hospital Review notes, Elevance expects about a -1.75 percent operating margin for its Medicaid business in 2026 and has already exited the Medicaid managed care program in Washington, D.C. in 2026, illustrating that while some segments are moving toward targeted profitability, others remain under pressure.
For investors, the contrast between a targeted positive operating margin of at least 2 percent in Medicare Advantage in 2026 and a negative margin of roughly -1.75 percent in Medicaid this year underlines a segmented risk profile: robust earnings contribution from senior-focused products versus ongoing restructuring and potential volatility in Medicaid. The reaffirmed full-year 2026 EPS guidance suggests that, in aggregate, management believes strengths in commercial and Medicare lines can offset weaker Medicaid profitability.
Analyst targets frame upside versus current price
Elevance Health stock is trading below several published analyst price targets, offering a numerical frame for potential upside if guidance is delivered. A recent analyst update highlighted that some targets, such as USD 492 from Wells Fargo and USD 424 from RBC, sit above or close to the latest closing levels, according to an article summary referenced in a market overview on September 15, 2026.
More specifically, Wells Fargo analyst Stephen Baxter maintains Elevance Health with a Buy rating and a target price of USD 473, as reported on September 15, 2026 by Futunn. At a spot price of around USD 423.00 as of September 15, 2026, that implies an upside of roughly USD 50 per share to the Wells Fargo target, or about 11.8 percent if the target were reached.
Stock trades within recent range with large-cap valuation
During the trading session dated September 15, 2026, Elevance Health shares traded between a low of USD 420.28 and a high of USD 427.17 on the NYSE, per Robinhood. The current indicated price of USD 423.00 sits about 0.6 percent above the day’s low and approximately 1.0 percent below the intraday high, showing a relatively tight intraday range as the market digests the reaffirmed guidance.
With a market capitalization of about USD 92,000,000,000 as referenced in the same overview on September 15, 2026, Elevance Health trades on a price-to-earnings ratio near 18.61 and carries a dividend yield cited at about 1.64 percent, according to Robinhood. For investors, that combination places the stock firmly in large-cap territory with a valuation multiple aligned with expectations for steady earnings growth and disciplined capital returns.
Elevance Health stock price snapshot
As of September 15, 2026, Elevance Health stock traded around USD 423.00 on the NYSE, within an intraday range of USD 420.28 to USD 427.17, on volume of about 1,090,000 shares, based on data cited by Robinhood.
Key data on Elevance Health stock
- Company: Elevance Health Inc.
- ISIN: US2855211023
- Ticker: ELV
- Trading venue: NYSE
- Price (as of September 15, 2026): 423.00 USD
- Market capitalization: 92,000,000,000 USD (as of September 15, 2026)
- Sector / Industry: Health care / Managed care
- Index membership: S&P 500
